Please login to the form below

Not currently logged in
Email:
Password:

MDD

This page shows the latest MDD news and features for those working in and with pharma, biotech and healthcare.

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage’s once-daily depression therapeutic has hit the primary endpoint in a pivotal phase 3 trial in patients with major depressive disorder (MDD), the companies announced today. ... The study enrolled adults aged 18 to 64 years who had MDD

Latest news

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....